Insights Into NTRK Gene Fusion-Positive Thyroid Cancer

Perspectives on drivers in treatment pathways for NTRK fusion-positive cancers

Southwest – March 29, 2022

Faculty Chair

Lori Wirth, MD

Massachusetts General Hospital, Boston, MA, USA

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

Example Report

Start discovering the insights

View Report


  • A moderated roundtable discussion was held with community oncologists from the Southwest US region in a virtual setting on March 29, 2022
  • Disease-state and data presentations were led by Dr Lori Wirth, Medical Director of Massachusetts General Hospital Center for Head and Neck Cancers, in conjunction with content developed by the Aptitude Health clinical team
  • Insights were obtained on the thyroid cancer disease landscape in the community setting, specifically testing protocols and treatment pathways for NTRK gene fusion-positive thyroid cancer


  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
  • The group of advisors comprises 13 oncologists from Arizona, California, Colorado, New Mexico, Nevada, and Utah

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.